APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, the most promising effect was exerted by apoA-I+CIGB-258, as evident in significantly ~3-fold (p < 0.05) reduced neutrophil counts in the hepatic section of the apoA-I+CIGB-258- treated group compared to the apoA-I- and CIGB-258-treated groups, testifying enhanced protective activity against CML-induced hepatotoxicity when using the combination of apoA-I+CIGB-258.